Royalty Pharma strikes another $1 billion dollar deal to acquire patent-backed revenue rights
Sales of drug earnings streams is an increasingly popular means of monetising life sciences innovations
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.